Skip to main content
. 2017 May 12;8(38):64344–64357. doi: 10.18632/oncotarget.17834

Figure 4. NK cell cytolytic activity to BPTF KD cells requires NCRs.

Figure 4

(A) Changes in NK receptor ligand expression measured by microarray in BPTF KD tumors harvested from NSG mice compared to controls. Hpse was measured independently by qRT-PCR because it was not on the microarray (* = ttest pvalue < 0.00002). (B-D) Percent target cell cytolytic activity by LDH assay. (B) NK-92 cells pretreated with anti-NKp46, anti-NKp30 or anti-NKG2D mAb were cocultured on 66cl4 targets at a 10:1 E:T ratio (n = 3 biological replicates, * = ttest pvalue < 0.05). (C) NK-92 cells pretreated with anti-NKp30 were cocultured with T47D targets at a 10:1 E:T ration (n = 3 biological replicates, * = ttest pvalue < 0.05). (D) Mouse NK cells pretreated with anti-NCR1 blocking mAb (clone mNCR1.15) were cocultured with 66cl4 targets at a 5:1 E:T ratio (n = 3 biological replicates, * = ttest pvalue < 0.04). (* = significant to no mAb Ctrl-sh1, ** = significant to the respective no mAb hairpin). (E) Representative flow cytometry histograms of NCR1-Ig binding to 67NR and 66cl4. (F) Fold change of MFI from D (n = 3 biological replicates, * = ttest pvalue < 0.03). (G) qRT-PCR analysis of Il-2 expression in Ncr1-ζ, Il-2 reporter BW cells incubated with control or BPTF KD cells for 48 hrs (n ≥ 3 biological replicates, * = ttest pvalue < 0.05). (H) 67NR and 66cl4 tumor weights harvested from untreated or mNCR1.15 treated BALB/c mice (n ≥ 4 biological replicates, * = ttest pvalue < 0.05). All quantitative data shown represent mean ± stdev.